The firm's ROS1 gene fusion kit was approved as a companion diagnostic for Pfizer's Xalkori.
The European Commission has now approved the anti-PD-1 therapy Keytruda, and the Dako test with it, as a first-line treatment for non-small cell lung cancer.
The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.
A team of Swedish researchers has received $3.3 million to develop a new nanotechnology platform for detecting blood-borne markers in lung and breast cancer.
Merck is hoping NanoString's multiplex platform can support gene expression signatures that will better predict which patients will respond to checkpoint inhibitors like its Keytruda.
The FDA-approved complementary assay "can provide insight into the survival benefit that may be achieved" with the treatment, Roche said.
OncoCyte is proceeding full-steam ahead on commercializing the gene expression-based test, pursuing CLIA certification and a Q2 2017 launch.
The FDA has approved Merck's Keytruda as a first-line treatment for non-small cell lung cancer in patients with high PD-L1 expression.
California researchers screened some 850 miRNAs to uncover one that inhibits growth in cancer cells with KRAS mutations, which are linked to poor survival.
The test can now be used to detect EGFR mutations in tissue and blood for lung cancer patients considering treatment with the tyrosine kinase inhibiting drugs Tarceva and Tagrisso.
In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.
Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.
Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.
British researchers say they've been removed from EU grant applications, according to the Guardian.